文献速递前列腺癌

验证[177Lu]Lu-PSMA-617对比卡巴他赛治疗转移性去势抵抗性前列腺癌的疗效反应预后与预测模型(TheraP):一项随机、开放标签、2期试验的事后分析

Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial.
PubMed 文献 · Eur Urol Oncol · 2024-04-06

本研究基于TheraP试验200例转移性去势抵抗性前列腺癌患者,评估既往开发的预后模型对[177Lu]Lu-PSMA-617对比卡巴他赛疗效的预测价值。结果显示PSA50模型具有预测和预后价值,而PSA无进展生存和总生存模型仅具预后价值。

要点

  • PSA50模型可预测[177Lu]Lu-PSMA-617对比卡巴他赛的PSA50反应。
  • favourable outcome组中[177Lu]Lu-PSMA-617的PSA50率为70%,卡巴他赛为36%。
  • PSA无进展生存和总生存模型无预测价值,仅具预后价值。

核心结论

  • 既往开发的PSA50结局分类模型对[177Lu]Lu-PSMA-617对比卡巴他赛后的结局既具预测性又具预后性。
  • PSA无进展生存和总生存模型仅具预后价值。

研究设计与样本

  • TheraP试验的事后分析,随机、开放标签、2期试验,200例患者随机接受[177Lu]Lu-PSMA-617(n=99)或卡巴他赛(n=101),随机时间2018年2月至2019年9月。

主要发现

  • favourable outcome分类患者中,[177Lu]Lu-PSMA-617组PSA50概率的比值比为6.36(95%CI 1.69-30.80),卡巴他赛组为0.96(95%CI 0.32-3.05),治疗与模型交互作用p=0.038。
  • favourable outcome患者中,[177Lu]Lu-PSMA-617组PSA50率为62/88(70%),卡巴他赛组为31/85(36%)。
  • 决策曲线分析显示,当PSA反应概率≥30%时,使用PSA50模型具有临床净获益。
  • PSA无进展生存和总生存模型的预测性能未确立(治疗与模型交互作用分别为p=0.36和p=0.41)。

关键数值与推荐

  • PSA50 favourable outcome分类:比值比6.36(95%CI 1.69-30.80)vs 0.96(95%CI 0.32-3.05),交互作用p=0.038。
  • PSA50率:62/88(70%)vs 31/85(36%)。
  • 决策曲线分析:PSA反应概率≥30%时PSA50模型有临床净获益。
  • PSA无进展生存模型交互作用p=0.36,总生存模型交互作用p=0.41。

临床怎么用

  • 作者认为这些模型可能帮助临床医生为一线化疗失败且适合[177Lu]Lu-PSMA-617和卡巴他赛的转移性去势抵抗性前列腺癌患者制定策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prognostic models have been developed using data from a multicentre noncomparative study to forecast the likelihood of a 50% reduction in prostate-specific antigen (PSA50), longer prostate-specific antigen (PSA) progression-free survival (PFS), and longer overall survival (OS) in patients with metastatic castration-resistant prostate cancer receiving [177Lu]Lu-PSMA radioligand therapy. The predictive utility of the models to identify patients likely to benefit most from [177Lu]Lu-PSMA compared with standard chemotherapy has not been established. OBJECTIVE: To determine the predictive value of the models using data from the randomised, open-label, phase 2, TheraP trial (primary objective) and to evaluate the clinical net benefit of the PSA50 model (secondary objective). DESIGN, SETTING, AND PARTICIPANTS: All 200 patients were randomised in the TheraP trial to receive [177Lu]Lu-PSMA-617 (n = 99) or cabazitaxel (n = 101) between February 2018 and September 2019. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Predictive performance was investigated by testing whether the association between the modelled outcome classifications (favourable vs unfavourable outcome) was different for patients randomised to [177Lu]Lu-PSMA versus cabazitaxel. The clinical benefit of the PSA50 model was evaluated using a decision curve analysis. RESULTS AND LIMITATIONS: The probability of PSA50 in patients classified as having a favourable outcome was greater in the [177Lu]Lu-PSMA-617 group than in the cabazitaxel group (odds ratio 6.36 [95% confidence interval {CI} 1.69-30.80] vs 0.96 [95% CI 0.32-3.05]; p = 0.038 for treatment-by-model interaction). The PSA50 rate in patients with a favourable outcome for [177Lu]Lu-PSMA-617 versus cabazitaxel was 62/88 (70%) versus 31/85 (36%). The decision curve analysis indicated that the use of the PSA50 model had a clinical net benefit when the probability of a PSA response was ≥30%. The predictive performance of the models for PSA PFS and OS was not established (treatment-by-model interaction: p = 0.36 and p = 0.41, respectively). CONCLUSIONS: A previously developed outcome classification model for PSA50 was demonstrated to be both predictive and prognostic for the outcome after [177Lu]Lu-PSMA-617 versus cabazitaxel, while the PSA PFS and OS models had purely prognostic value. The models may aid clinicians in defining strategies for patients with metastatic castration-resistant prostate cancer who failed first-line chemotherapy and are eligible for [177Lu]Lu-PSMA-617 and cabazitaxel. PATIENT SUMMARY: In this report, we validated previously developed statistical models that can predict a response to Lu-PSMA radioligand therapy in patients with advanced prostate cancer. We found that the statistical models can predict patient survival, and aid in determining whether Lu-PSMA therapy or cabazitaxel yields a higher probability to achieve a serum prostate-specific antigen response.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gafita A, Martin AJ, Emmett L, et al. Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial. Eur Urol Oncol. 2024. PMID: 38584037. doi:10.1016/j.euo.2024.03.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。